18.5 %

excelent co

PE of 13, a PEG of 1.75, and a yield of 11.8%.

Canadian drug developer Biovail Corp. said that its board has authorized the repurchase of up to 14 million shares of common stock over the next year.

Biovail had 161 million shares outstanding, as of May 8.

The repurchases will be funded using existing cash, the company said.

The program does not require Biovail to buy back a minimum number of shares and may be suspended or terminated at any time.

Its board also has approved a quarterly cash dividend of 37.5 cents.

12.5%

Cheap

14.57 trailing price/earnings, 0.297 debt/equity, greater than 100% pre-tax return on capital.

Market Maker

yield & potential for breakout

n/t

Stock continues to fall over legal issues and poor management

Slow to recover from last summer's swoon